Autres langues SymBio Pharmaceuticals Limited

Actions

4582

JP3383050006

Temps Différé Japan Exchange Autres places de cotation 04:29:41 26/04/2024			Varia. 5j.	Varia. 1 janv.
176 ^JPY	-1,12 %		+1,15 %	-28,74 %

13/02	Les bénéfices de SymBio Pharmaceuticals pour l'exercice 2023 ne correspondent pas aux prévisions en raison d'une perte d'exploitation plus élevée que prévu	MT
08/02	SymBio Pharmaceuticals Limited fournit des prévisions de résultats pour l'exercice 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	19/04
SymBio Pharmaceuticals Limited amended terms of the transaction	18/03
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	13/02
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	08/02
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	08/02
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	15/11
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	14/11
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	14/11
SymBio Pharmaceuticals Limited amended terms of the transaction	10/11
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	06/10/23
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	03/08/23
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	03/08/23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	27/04/23
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	25/04/23
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	24/04/23
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	22/03/23
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	16/03/23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SymBio Pharmaceuticals Limited

Actions

4582

JP3383050006

Autres langues

Filtres